Oruka Therapeutics SVP sells 9,999 shares

Oruka Therapeutics' Senior Vice President, Finance, reported sales under a Rule 10b5-1 trading plan entered into February 11, 2026.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) Senior Vice President, Finance Arjun Agarwal exercised options for 9,999 common shares on October 12, 2026: 8,541 shares at an exercise price of $12.50 per share and 1,458 at $34.39 per share. He also reported sales totaling 9,999 shares that day. The sales were made under a Rule 10b5-1 trading plan entered into on February 11, 2026.

Insider Trade Summary 10b5-1

Exercise and Sale: 9,999 shares ($649K approx. pre-tax spread)

Exercise and Sale 8 txns

Insider Agarwal Arjun

Role Senior Vice President, Finance

Sold 9,999 shs ($806K)

Approx. gross sale proceeds $806K

Approx. exercise cost $157K

Approx. pre-tax spread $649K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy) F6	8,541	$0.00	$0.00
Exercise	Employee Stock Option (right to buy) F7	1,458	$0.00	$0.00
Exercise	Common Stock	8,541	$12.50	$107K
Exercise	Common Stock	1,458	$34.39	$50K
Sale	Common Stock F1, F2	5,741	$80.0302	$459K
Sale	Common Stock F1, F3	2,100	$80.7601	$170K
Sale	Common Stock F1, F4	1,958	$81.8551	$160K
Sale	Common Stock F1, F5	200	$82.835	$17K

Holdings After Transaction: Employee Stock Option (right to buy) — 133,251 contracts (Direct); Common Stock — 14,219 shares (Direct)

Footnotes (7)

1. F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.55 to $80.54, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.56 to $81.53, inclusive.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.61 to $82.50, inclusive.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $82.91, inclusive.
6. F6. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
7. F7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

Key Figures

Option exercise: 8,541 shares at $12.50 per share Option exercise: 1,458 shares at $34.39 per share Shares sold: 5,741 shares at a weighted average price of $80.0302 per share +3 more

6 metrics

Option exercise 8,541 shares at $12.50 per share October 12, 2026

Option exercise 1,458 shares at $34.39 per share October 12, 2026

Shares sold 5,741 shares at a weighted average price of $80.0302 per share October 12, 2026; transaction prices ranged from $79.55 to $80.54

Shares sold 2,100 shares at a weighted average price of $80.7601 per share October 12, 2026; transaction prices ranged from $80.56 to $81.53

Shares sold 1,958 shares at a weighted average price of $81.8551 per share October 12, 2026; transaction prices ranged from $81.61 to $82.50

Shares sold 200 shares at a weighted average price of $82.8350 per share October 12, 2026; transaction prices ranged from $82.76 to $82.91

Key Terms

Rule 10b5-1 trading plan, weighted average price, vests

3 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vests financial

"The option vests as to 1/48 of the underlying shares monthly"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

At what prices did ORKA Senior Vice President, Finance Arjun Agarwal sell shares?

On October 12, 2026, he reported four sale groups: 5,741 shares at a weighted average price of $80.0302 per share, within a range of $79.55 to $80.54; 2,100 at $80.7601, within $80.56 to $81.53; 1,958 at $81.8551, within $81.61 to $82.50; and 200 at $82.8350, within $82.76 to $82.91. Each reported price was a weighted average.

How did ORKA Senior Vice President, Finance Arjun Agarwal's exercised options vest?

The option covering 8,541 shares vests as to 1/48 of the underlying shares monthly from January 1, 2025. The option covering 1,458 shares vests as to 1/48 of the underlying shares monthly from January 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 04:34 PM EDT Accepted by SEC EDGAR 10/13/2026 - 04:34 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agarwal Arjun

(Last) (First) (Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President, Finance

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/12/2026		M		8,541	A	$12.5	22,760	D
Common Stock	10/12/2026		M		1,458	A	$34.39	24,218	D
Common Stock	10/12/2026		S(1)		5,741	D	$80.0302(2)	18,477	D
Common Stock	10/12/2026		S(1)		2,100	D	$80.7601(3)	16,377	D
Common Stock	10/12/2026		S(1)		1,958	D	$81.8551(4)	14,419	D
Common Stock	10/12/2026		S(1)		200	D	$82.835(5)	14,219	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$12.5	10/12/2026		M			8,541	(6)	01/21/2035	Common Stock	8,541	$0	76,376	D
Employee Stock Option (right to buy)	$34.39	10/12/2026		M			1,458	(7)	01/22/2036	Common Stock	1,458	$0	56,875	D

Explanation of Responses:

1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.55 to $80.54, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.56 to $81.53, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.61 to $82.50, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.76 to $82.91, inclusive.

6. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

7. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

	/s/ Paul Quinlan, as attorney-in-fact for Arjun Agarwal	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)